Replies to post #108964 on Biotech Values

[jq1234]

I agree superiority needs to use ITT analysis.

With superiority label Xarelto market share relative to Pradaxa market share will be MUCH bigger because of Xarelto once a day regimen advantage over Pradaxa twice a day regimen. Without superiority label, I would say the regimen advantage is probably gone. JNJ/Bayer marketing power probably can limit the damage of label limitation.